What Does Anandamide Do to the Brain?

Anandamide is the brain’s own cannabis-like molecule, and it touches nearly every aspect of how you think, feel, and cope with stress. First isolated from pig brain tissue in the early 1990s, anandamide was the first compound produced inside the body shown to activate the same receptor that THC targets: the CB1 cannabinoid receptor.¹ Its name comes from the Sanskrit word “ananda,” meaning bliss, which hints at its reputation. But anandamide does far more than produce pleasant feelings. It helps regulate pain, fear, memory, appetite, sleep, inflammation, and even how your brain develops and repairs itself.

How Anandamide Signals in the Brain

Most chemical messengers in the brain travel in one direction: from the sending neuron to the receiving neuron. Anandamide breaks that rule. It is made on demand in the receiving (postsynaptic) neuron and then travels backward to the sending (presynaptic) neuron, where it activates CB1 receptors. This “retrograde” signaling acts like a volume knob, dialing down the release of other neurotransmitters and fine-tuning communication between neurons. Compared to the other major endocannabinoid, 2-AG, which delivers fast, point-to-point retrograde signals, anandamide tends to operate more slowly and can also act through non-retrograde routes, including the vanilloid receptor TRPV1.²

This dual identity matters. When anandamide activates CB1 receptors, it generally dampens neural activity, reducing excitatory or inhibitory signals depending on the circuit. When it activates TRPV1 channels instead, it can have the opposite effect, sometimes increasing pain signaling or influencing different forms of synaptic plasticity. The balance between these two receptor targets, and which one anandamide preferentially engages, depends on the local concentration and the tissue involved.³

Pain Modulation

One of anandamide’s most studied roles is in pain processing. In the spinal cord, anandamide acts as a modulator of pain signals, working through both CB1 and TRPV1 receptors on the presynaptic side of pain-transmitting neurons.³ The practical result depends on concentration: at lower levels, anandamide primarily engages CB1 receptors and reduces pain signaling, while at higher concentrations TRPV1 activation can come into play and complicate the picture.

Research in animal models of nerve injury has shown that blocking the enzyme that breaks down anandamide (called FAAH) leads to pain relief in the spinal cord, and this relief depends on CB1 or a combination of CB1 and TRPV1 receptors depending on the dose.⁴ Mice that completely lack FAAH have roughly fifteen times the normal brain levels of anandamide and show measurably reduced pain sensitivity, an effect that disappears when their CB1 receptors are blocked.⁵ Those findings established FAAH as a key gatekeeper: how quickly your body breaks down anandamide determines how much pain-dampening tone the molecule provides at any given moment.

Fear, Stress, and Emotional Regulation

Anandamide plays a significant role in how the brain processes fear and learns that something previously threatening is now safe. In the amygdala, the brain region central to fear processing, anandamide levels rise during extinction training, the process by which a fear association gradually weakens. Boosting anandamide specifically within the amygdala by blocking FAAH there was enough to promote long-term depression of inhibitory synapses, a form of rewiring linked to successful fear extinction.⁶ When that amygdala CB1 signaling was blocked with an antagonist, the fear-reducing benefits vanished, confirming the amygdala as the key site of action.

The endocannabinoid system, including anandamide, is densely expressed in the limbic system and prefrontal cortex, the brain areas that evaluate threats and regulate stress responses.⁷ This positioning helps explain why disruptions in anandamide signaling are linked to exaggerated stress responses and difficulty recovering emotionally from threatening experiences.

A Genetic Variation That Changes Anxiety Levels

Not everyone breaks down anandamide at the same rate. A naturally occurring variant in the gene for FAAH (called C385A, or rs324420) produces a less stable version of the enzyme. People who carry this A-allele variant effectively have higher circulating anandamide because their FAAH is less efficient at destroying it. In a study of 137 people, A-allele carriers reported lower levels of trait anxiety, and this finding was replicated in a separate group tested during a fear-extinction task.⁸ Mice engineered with the equivalent mutation showed the same behavioral pattern: less anxiety and enhanced connectivity between the frontal cortex and amygdala.

This is one of the clearer examples of how anandamide tone, the baseline level of anandamide your brain maintains, translates directly into emotional temperament. People whose genetics give them naturally elevated anandamide may walk through life with a subtle but real buffer against anxiety. That said, this is one gene variant affecting one enzyme in a complex system; temperament is shaped by hundreds of genetic and environmental factors, so carrying the A-allele is far from a guarantee of being stress-free.

Reward, Motivation, and Dopamine

Anandamide participates in the brain’s reward circuitry. When anandamide is administered intravenously to rats, it increases dopamine release in the nucleus accumbens shell, the same region that lights up in response to food, sex, and most drugs of abuse.⁹ This dopamine boost is thought to be part of how anandamide helps signal that something is rewarding or worth repeating.

The picture gets more nuanced when you look at local circuits within the nucleus accumbens itself. Blocking FAAH to raise anandamide levels inside the accumbens decreases dopamine release that is triggered by a specific type of local neuron (cholinergic interneurons), and this suppression depends on CB1 receptors.¹⁰ So anandamide does not simply turn dopamine up or down uniformly. It shapes which inputs get amplified and which get muted, acting more like an editor than an accelerator within the reward system.

The Runner’s High

For decades, the euphoria and calm you feel after a good run were attributed to endorphins. That story is probably wrong, or at least incomplete. A study of 63 people found that 45 minutes of moderate-intensity running on a treadmill increased both euphoria and plasma levels of anandamide. Crucially, when researchers blocked opioid receptors with naltrexone, the euphoria and anxiety reduction still happened, and anandamide levels still rose.¹¹ If endorphins were the primary cause, blocking them should have erased the effect. It did not.

A broader review of exercise research concluded that acute aerobic exercise consistently activates the endocannabinoid system, with significant increases in anandamide after both self-paced and prescribed-intensity workouts. These increases in circulating endocannabinoids tracked with the hallmarks of the runner’s high: less anxiety and more euphoria.¹² The current thinking is that endorphins may contribute to pain tolerance during exercise, but the mood lift and anxiety reduction afterward are likely driven by anandamide and related endocannabinoids rather than opioids.

Protecting Neurons from Inflammation

When the brain is injured or inflamed, anandamide levels rise, and this appears to be a protective response rather than a bystander effect. Research on brain tissue slices showed that anandamide effectively abolished the secondary damage caused by invading immune cells (microglia) after an excitotoxic insult, even though it could not prevent the initial injury itself.¹³ The mechanism involves anandamide acting on CB1 and CB2 receptors on microglia to rapidly switch on a protein called MKP-1, which dials down the inflammatory cascade.

This anti-inflammatory role extends to shifting the overall character of the microglial response. Microglia can adopt a neurotoxic profile or a more protective one. In cell cultures exposed to bacterial toxins, anandamide pretreatment significantly reduced markers of the neurotoxic profile, and this effect was primarily mediated through CB2 receptors.¹⁴ The finding that anandamide protects neurons not by shielding them directly but by calming the immune cells around them has made FAAH inhibition an area of interest for neuroinflammatory conditions.

How Anandamide Is Made and Destroyed

Unlike stored neurotransmitters that wait in vesicles to be released, anandamide is built from membrane components on the spot when needed. The main pathway involves clipping a fatty molecule called NAPE out of the cell membrane using an enzyme called NAPE-PLD. But when researchers knocked out that enzyme in mice, anandamide levels barely changed, revealing that backup routes exist.¹⁵ At least two parallel pathways can produce anandamide from the same starting material through different intermediate steps.¹⁶ This redundancy underscores how important anandamide signaling must be: the brain has evolved multiple ways to ensure it keeps flowing.

Destruction is simpler and faster. FAAH is the primary enzyme responsible, and it works quickly enough that anandamide’s effects in a living brain are normally brief and localized. Mice without FAAH show dramatically amplified and prolonged responses to anandamide, including reduced movement, pain relief, muscle rigidity, and lowered body temperature, all classic cannabinoid effects that are reversed by CB1 blockers.⁵ FAAH essentially keeps anandamide on a short leash, preventing the molecule from flooding circuits the way THC does.

Anandamide and Sleep

Your anandamide levels are not constant throughout the day. In healthy humans, plasma anandamide concentrations follow a circadian rhythm, peaking at about three times higher upon waking compared to just before sleep. Sleep deprivation disrupts this pattern.¹⁷ Rat studies have added anatomical detail, showing that anandamide fluctuates differently across brain regions over a 24-hour cycle. In cerebrospinal fluid, concentrations rise during the rest phase and drop during the active phase, while in the pons and hippocampus the rhythm runs in the opposite direction, with peaks during wakefulness.¹⁸

The working hypothesis is that anandamide accumulates in brain tissue during waking hours and then gets released into the cerebrospinal fluid during rest, where it helps regulate transitions between sleep and wakefulness. This circadian dimension means that sleep disruption does not just make you tired; it may alter your endocannabinoid tone in ways that ripple into pain sensitivity, mood, and appetite the next day.

Brain Development

Anandamide is not just a modulator of the adult brain. The endocannabinoid system is active from embryonic development onward, helping to guide the sequence of events that builds a working brain: the birth of new neurons, their migration to the right locations, the growth of axons and dendrites toward their targets, and the refinement of synaptic connections.¹⁹ In mouse neural progenitor cells, anandamide treatment influenced cell fate, initially steering cells toward becoming support cells (glia) and subsequently promoting the formation of neurons.²⁰

This developmental role is one reason researchers worry about heavy cannabis use during adolescence. THC floods the same receptors that anandamide carefully tunes during brain maturation, and because THC is not broken down as rapidly or locally as anandamide, it overrides the fine spatial and temporal control the endocannabinoid system normally exerts. The developing brain’s reliance on precisely calibrated endocannabinoid signaling makes it particularly vulnerable to external disruption.

How Diet Influences Anandamide Levels

Because anandamide is built from arachidonic acid, a fatty acid derived from dietary omega-6 fats, the composition of your diet can shift endocannabinoid tone. Long-term supplementation with omega-3 fatty acids (DHA and EPA, found in fish oil) has been shown to reduce levels of anandamide and 2-AG, while increasing levels of structurally similar but functionally different molecules derived from DHA and EPA themselves.²¹ In other words, what you eat does not just provide calories; it changes the raw materials available for endocannabinoid production, which in turn adjusts signaling throughout the system.²²

A diet heavily weighted toward omega-6 fats (common in many Western diets rich in seed oils and processed foods) supplies abundant arachidonic acid, potentially sustaining higher baseline anandamide production. A diet richer in omega-3s tilts the balance toward the DHA- and EPA-derived analogs, which may have their own receptor interactions and anti-inflammatory properties. The practical upshot is that long-term dietary patterns can quietly reshape your endocannabinoid landscape, with downstream effects on inflammation, mood, and appetite regulation.

Why Anandamide Is Not Just “Natural THC”

It is tempting to think of anandamide as the body’s version of THC, and the comparison is useful up to a point: both molecules activate CB1 receptors and produce overlapping effects like pain relief and relaxation. But the differences matter more than the similarities. Anandamide is produced locally at the synapse where it is needed, acts for seconds before FAAH destroys it, and never reaches high concentrations across large brain regions simultaneously. THC, by contrast, arrives everywhere at once via the bloodstream, lingers for hours because the body lacks a dedicated fast-acting enzyme to clear it, and activates CB1 receptors in circuits that anandamide would normally leave untouched.

Anandamide is also a partial agonist at CB1, meaning it activates the receptor less fully than THC does. And it engages TRPV1 channels in ways that THC does not, adding a layer of complexity to its signaling that has no parallel in the cannabis experience. The FAAH-knockout mice mentioned earlier illustrate this distinction well: even with fifteen-fold higher brain anandamide, their behavior showed classic cannabinoid effects but nothing resembling the intense psychoactive state produced by a large dose of THC.⁵ Anandamide whispers where THC shouts.

Therapeutic Prospects for FAAH Inhibitors

If boosting anandamide reduces anxiety, dampens pain, and protects neurons, then blocking the enzyme that destroys it seems like an obvious drug strategy. FAAH inhibitors have been tested clinically, but the results have been more complicated than the preclinical data suggested. For pain specifically, FAAH inhibitors have not proven effective enough on their own to become treatments. Where they show more promise is in psychiatric conditions: early evidence points toward potential usefulness for post-traumatic stress disorder and cannabis use disorder.²³

The disconnect between dramatic animal findings and modest human results likely reflects the fact that anandamide is just one of many molecules broken down by FAAH, and raising all of them simultaneously does not produce a clean signal. There was also a tragic safety failure in 2016 when a different class of FAAH inhibitor caused severe neurological harm in a French clinical trial, though the compound involved turned out to have significant off-target activity unrelated to FAAH. The field has continued cautiously, with better-designed inhibitors and more targeted approaches focusing on specific conditions where the amygdala-centered fear-extinction mechanism is most relevant.

An Ancient Signaling System

Endocannabinoid signaling is not a recent evolutionary invention. CB1- and CB2-type receptors appear to have originated in a common ancestor of all living chordates. In the sea squirt Ciona intestinalis, a CB1/CB2-type receptor is already targeted specifically to axons, suggesting that using cannabinoid receptors to regulate neural signaling is an extremely old arrangement.²⁴ Even in animals that lack cannabinoid receptors entirely, such as leeches, endocannabinoids like 2-AG still function as retrograde signals by activating different presynaptic targets. The enzymes for making and breaking down endocannabinoids appear across the animal kingdom, while the specific receptors vary, which suggests the molecules came first and different receptor systems were recruited to detect them over evolutionary time. For anandamide, this deep history helps explain why it is woven into so many distinct brain functions rather than being dedicated to a single task.

1
Proceedings of the National Academy of Sciences. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
2
Current Opinion in Neurobiology. Endocannabinoid-mediated retrograde modulation of synaptic transmission
3
PubMed. Dual effect of anandamide on spinal nociceptive transmission in control and inflammatory conditions
4
PubMed. Spinal anandamide produces analgesia in neuropathic rats: possible CB(1)- and TRPV1-mediated mechanisms
5
Proceedings of the National Academy of Sciences. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
6
PubMed Central. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity
7
PubMed Central. The endocannabinoid system in modulating fear, anxiety, and stress
8
Nature Communications. FAAH genetic variation enhances fronto-amygdala function in mouse and human
9
PubMed. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats
10
Neuron. Cannabinoid CB1 Receptors on Cortical Afferents Modulate Dually Triggered Dopamine Release in the Nucleus Accumbens
11
PubMed. Exercise-induced euphoria and anxiolysis do not depend on endogenous opioids in humans
12
PubMed Central. Do Endocannabinoids Cause the Runner’s High? Evidence and Open Questions
13
PubMed. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells
14
Neural Plasticity. Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures
15
PubMed Central. Multiple pathways involved in the biosynthesis of anandamide
16
Proceedings of the National Academy of Sciences. A biosynthetic pathway for anandamide
17
PubMed Central. Endocannabinoid signalling: has it got rhythm?
18
PubMed. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat
19
PubMed Central. Cannabis, Endocannabinoids and Brain Development: From Embryogenesis to Adolescence
20
PubMed. Regulation of neural progenitor cell fate by anandamide
21
Lipids. Interplay Between n‐3 and n‐6 Long‐Chain Polyunsaturated Fatty Acids and the Endocannabinoid System in Brain Protection and Repair
22
Molecular Nutrition & Food Research. Effect of dietary fat on endocannabinoids and related mediators: Consequences on energy homeostasis, inflammation and mood
23
Journal of Internal Medicine. The endocannabinoid system – current implications for drug development
24
PubMed Central. The evolution and comparative neurobiology of endocannabinoid signalling